ESTA
Establishment Labs Holdings Inc.74.15
+2.12+2.94%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms momentum, details execution.
Q&A reinforced prepared remarks' upbeat tone on US Motiva ramp and Preserve potential, while adding execution details for investors. Management confirmed nearly 10 of 15 new sales reps—seasoned veterans—are already aboard to deepen penetration across 1,500+ accounts, where shares lag in newer ones. Preserve could claim 50% of US revenue by 2027-28, doubling ASPs versus standard cases for margin tailwinds. Reconstruction emerges as a 2027 priority with hybrid reps tapping 200 Flora sites. Markets stay healthy, China improves. No hedges; watch Preserve uptake and account depth.
Key Stats
Market Cap
2.15BP/E (TTM)
-Basic EPS (TTM)
-2.84Dividend Yield
0%Recent Filings
10-K
FY2025 10-K filed
Establishment Labs Holdings Inc. filed its 10-K for FY2025 ended December 31, 2025, but financial statements and MD&A results not disclosed in the provided filing. No revenue, profitability, EPS, or quarterly breakdowns available. The filing highlights a new CFO employment agreement effective March 9, 2026, with $550,000 base salary, up to 50% target bonus, and $700,000 new hire cash award. Q4 momentum undisclosed. Liquidity and capital allocation not detailed. Supply chain disruptions pose a key risk to potential quarterly performance.
8-K
Q4 revenue up 45.2%
Establishment Labs crushed Q4 2025 with revenue surging 45.2% to $64.6 million, full-year sales up 27.2% to $211.1 million, and adjusted EBITDA flipping to positive $5.5 million. U.S. Motiva revenue hit $17.3 million in the quarter. Cash stands at $75.6 million. Guidance calls for 25.1-26.0% revenue growth to $264-266 million in 2026.
8-K
JPM Conference presentation filed
8-K
Q4 revenue $64-65M
Establishment Labs released preliminary Q4 2025 revenue of $64.0-$65.0 million, including $17.0-$17.5 million from U.S. Motiva sales, driving full-year revenue to $210.5-$211.5 million—up 27% over 2024. Cash climbed to $75.5 million, up $4.8 million sequentially. Record quarter. Management eyes free cash flow positivity in 2026 amid unaudited forward-looking estimates.
10-Q
Q3 FY2025 results
Establishment Labs drove Q3 revenue to $53.8M, up 33.8% y/y from $40.2M, with North America surging post-FDA approval while EMEA dipped slightly; gross margin expanded to 70.1% from 63.9% on higher U.S. pricing. Operating loss narrowed to $4.0M from $13.1M as revenue gains outpaced SG&A growth, yet net loss widened to $11.1M from $16.7M due to higher interest expense on expanded debt. Cash fell to $70.6M after $50.7M operating burn, offset by $24.5M Tranche D draw; note payable hit $246.5M (maturing 2027). Closed Motiva Benelux/NL acquisition in Oct 2024 for $7.8M (cash/stock/contingent), recognizing $1.5M finite-lived intangibles (10 years). U.S. launch fuels momentum, but single-source silicone supply poses risks.
IPO
Employees
Sector
Industry
ABT
Abbott Laboratories
126.86-1.61
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
ELUT
Elutia, Inc.
0.55-0.13
ENOV
Enovis Corporation
26.07-0.47
INMD
InMode Ltd.
14.48+0.15
RMSL
RemSleep Holdings, Inc.
0.00+0.00
TELA
TELA Bio, Inc.
1.18+0.05
VERO
Venus Concept Inc.
2.26+0.59
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52
ZIMV
ZimVie Inc.
18.99+0.00